Background
MicroRNAs (miRNAs) have very important roles in the regulation of gene expression. The miRNA biogenesis is a multistep processes in mammalian. Conventionally, miRNAs are firstly transcribed by RNA polymerases II and III as primary miRNAs (pri-miRNAs) [
1]. These pri-miRNAs are later processed to the 65-nucleotide (nt) hairpin precursor miRNAs (pre-miRNAs) by the microprocessor complex (MC), which is mainly composed of Drosha and DGCR8 [
2]. Then pre-miRNAs are transported by Exportin-5/Ran-GTP from the nucleus to the cytoplasm [
3], where further they are accurately cleaved into an ~20–25 bp double-stranded mature miRNAs by the Dicer-TARBP2 complex [
4]. The mature miRNA, one strand of the duplex, and Argonaute (Ago) proteins mainly constitute a RNA-induced silencing complex (RISC), which mediates posttranscriptional gene silencing [
5,
6].
KHSRP, a hnRNP K homology (KH)-type splicing regulatory protein, has been identified as a main component of the Drosha complex to promote the biogenesis of a select group of miRNAs [
7,
8]. KHSRP contains four KH domains that bind to the single-stranded nucleic acids, and specifically to short G-rich stretches in the terminal loop (
TL-G-rich) of primary/precursor miRNAs, which favors the maturation of a subset of miRNAs including let-7 family [
7‐
10]. In addition, KHSRP also participates in pre-mRNA splicing [
11,
12], mRNA decay [
13,
14]. KHSRP seems to contain a nuclear localization signal (NLS) which can mediate its shuttling between the nucleus and the cytoplasm [
7,
15,
16], however the mechanism underlying the translocation of KHSRP is unclear.
SUMO (small ubiquitin-like modifier) is a reversible protein modifier, including SUMO 1–4 in human [
17,
18]. SUMOylation plays critical roles in a variety of cellular processes through regulating the activity [
19], stability [
20] or localization [
21] of target proteins. In particular, SUMOylation can promote the target protein nuclear import, for example, SUMOylated RanGAP1 mostly localizes in the nucleus while the unmodified RanGAP1 is cytosolic [
22,
23]. However SUMOylation can also increase the target protein nuclear export, for instance, SUMOylation of p53 promotes its nuclear export [
24,
25]. Recently we have reported that SUMOylation of TARBP2 and DGCR8 is involved in the regulation of the miRNA pathway [
20,
26,
27].
Here we identified that KHSRP was modified by SUMO1 at the major site K87 in vitro and in cells for the first time. We found that KHSRP SUMOylation was upregulated by the microenvironmental hypoxia while downregulated by growth factors. SUMOylation could facilitate KHSRP translocation from the nucleus to the cytoplasm. More importantly, KHSRP SUMOylation inhibited the biogenesis of a subset of TL-G-rich miRNAs, which was probably contributed to SUMOylation promoting the disassociation of KHSRP from the pri-miRNA/Drosha-DGCR8 complex. Furthermore, we observed that the dysregulation of TL-G-Rich miRNAs such as the members of let-7 family mediated by KHSRP SUMOylation was linked to tumorigenesis and cancer progression.
Discussion
We recently reported that SUMOylation is involved in the regulation of miRNA pathways. TARBP2 SUMOylation does not influence the biogenesis of mature miRNAs, but it enhances the gene-silencing efficiency of miRNAs and suppresses tumor progression [
26]. DGCR8 SUMOylation majorly occurs at two sites K707 and K259. K707-SUMOylation of DGCR8 increases its affinity with pri-miRNAs and directs the function of pri-miRNAs in oncogenic gene silencing, which promotes tumorigenesis and tumor cell migration [
20]. However, K259-SUMOylation of DGCR8 promoted by the tumor suppressor p14ARF mainly maintains its nuclear localization to function as a partner of Drosha in the MC complex, which prevents the aberrant miRNA biogenesis and exerts its tumor-suppressive function [
27]. KHSRP exists in the Drosha-DGCR8 complex as a single stranded RNA binding protein and promotes a subset of miRNAs biogenesis [
7‐
10]. Here we demonstrated for the first time that SUMOylation of KHSRP regulates the
TL-G-Rich miRNA biogenesis (Fig.
4c-
e; Additional file
8: Table S2, Additional file
9: TableS3 and Additional file
10: Table S4), which is a novel function of SUMOylation in the miRNA pathways.
We identified that KHSRP was modified by SUMO1 at the major site K87 (Figs.
1,
2 and Additional file
2: Fig. S2, Additional file
3: Fig. S3) adjacent to its nuclear localization signal or sequence (NLS) of KHSRP, which suggested that SUMOylation is involved in the regulation of nucleocytoplasmic transport. In most cases, SUMOylation promotes the nuclear import of target proteins, such as SUMOylation of RanGAP1, ZIC3 and JAK2 [
22,
23,
43,
44]. But interestingly, in this study we found that SUMOylation of KHSRP promotes its nuclear export (Fig.
5), as like SUMOylation of p53 [
24,
25]. SUMO1-KHSRP gene fusion mimicking SUMOylated status increased the cytoplasmic localization (Fig.
5c-
d), but we could not exclude the possibility that SUMO1 fusion at the N terminus might affect the nuclear localization. However the cytoplasmic localization of KHSRP was increased by knockdown of SENP1, or under hypoxia environment, or stimulation by LY294002, for high-SUMOylation status (Fig.
5e-
f, Additional file
13: Fig. S9 and Additional file
14: Fig. S10), and by co-expression of SUMO1 (Fig.
5b), which was similar to the translocation pattern of the NLS-deleted KHSRP (Fig.
5d). In agreement with these, the SUMO-site mutant KHSRP-K87R existed almost in the nucleus (Fig.
5a-
b). Thus, we come to a conclusion that the translocation of KHSRP from the nucleus to the cytoplasm is partially controlled by SUMOylation.
KHSRP can recognize and bind to
TL-G-Rich the terminal loop (TL) of a subset of miRNA precusors which harbor short G-rich sequences, and promote their processing to mature miRNAs [
7,
9,
10]. Among these miRNAs, the let-7 family, which are important tumor suppressor miRNAs [
46,
47], are the most classic examples of KHSRP positively regulating miRNA biogenesis [
7,
10]. Indeed, 151 miRNAs including let-7 family were down-regulated due to KHSRP knockdown (Fig.
4c; Additional file
9: Table S3). We observed that SUMOylation promotes translocation of KHSRP from the nucleus to the cytoplasm, which probably explained why the binding of Drosha-DGCR8 complex with KHSRP-K87R was increased compared to that with KHSRP-WT (Fig.
4a-
b). As expectedly, 51 miRNAs including let-7i, let-7g, let-7e and miR-98 were up-regulated by the mutant KHSRP-K87R compared with by KHSRP-WT (Fig.
4c-
d; Additional file
10: Table S4). Moreover, by using the RNAstructure software, we analyzed the secondary structures to show short G-rich stretches in the terminal loop of these pri-miRNAs (Additional file
10: Table S4), for instances, pri-let-7a-1, pri-let-7a-3, pri-let-7e, pri-let-7g, pri-let-7i, miR-98 and pri-miR-182 (Fig.
6a). The RIP and qPCR assays revealed that the fusion of SUMO1 to the KHSRP obviously inhibited its interaction with pri-let-7a-1 thus leading to the decrease of mature let-7a (Fig.
6b), whereas the SUMO-site mutant KHSRP-K87R extremely enhanced the interaction between KHSRP and pri-let-7a-1 or pri-let-7a-3 thereby resulting in the increase of mature let-7a (Fig.
6c-
d). Therefore, besides altering its translocation, SUMOylation of KHSRP directly interfered its binding to pri-miRNAs, which also contributed to KHSRP SUMOylation inhibiting the biogenesis of a subset of miRNAs. The third KH domain (KH3) of KHSRP recognizes short G-rich sequences in the pre-let-7 terminal loop and dominates the interaction [
10], but it is not clear whether SUMOylation of the protein influences the formation of the KH3-pri-miRNA complex.
The miRNA pathways are involved in diverse physiological and pathological processes including cancer. Impaired microRNA processing enhances cellular transformation and tumorigenesis by knockdown of the components of the miRNA processing machinery such as Dicer and Drosha [
48]. TARBP2 recruiting Dicer to Ago2 constitutes an RNA-induced silencing complex (RISC)-loading complex (RLC) for miRNA processing and gene silencing [
26,
49], and recently we discovered SUMOylation of TARBP2 plays roles in suppression of tumor growth and tumor cell migration by regulating miRNA efficiency rather than influencing the mature miRNA production [
26]. DGCR8 is the most important binding partner protein of Drosha, and most recently we found that DGCR8 can be SUMOylated at two sites with reverse functions of each other, showing that SUMOylation at K707 promotes tumorigenesis [
20] while SUMOylation at K259 suppresses tumorigenesis [
27]. KHSRP is also a very important component of the Drosha/DGCR8 complex, and here we for the first time found that KHSRP SUMOylation was also linked to tumorigenesis and cancer progression. The abilities of soft-agar colony formation, migration, invasion and xenografted tumor growth were increased when KHSRP stably knockdown in DU145 cells (Fig.
3a-
e), which was attributed to downregulation of
TL-G-Rich miRNAs (Fig.
4c; Additional file
9: Table S3). This suggested that KHSRP plays a key role in tumor-suppression. Compared with KHSRP-WT, re-expression of KHSRP-K87R into stable cell line DU145-shKHSRP, a subset of miRNAs such as let-7 family were upregulated (Fig.
4d-
e; Additional file
10: Table S4) and consequently the tumor-suppressive capabilities were enhanced (Fig.
3a-e).
Methods
Cell cultures and transfections
Human embryonic kidney 293T, 293FT, HeLa and prostate cancer DU145 cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM, obtained from Hyclone) containing 10% fetal calf serum (Biowest, Kansas, MO, USA), 1% penicillin and streptomycin (Invitrogen). All cell lines were cultured at 37 °C in a 5% CO2 humidified incubator. Cell transfection was performed using Lipofectamine 2000 (Invitrogen).
Reagents and antibodies
Antibody against KHSRP (#A302–021) was from Bethyl Laboratories, Inc. (Montgomery, UK). Tubulin-Alpha mouse Mcab (#66031–1-Ig), His-Tag mouse antibody (#66005–1-Ig), GST mouse antibody (#66001–1-Ig) were from Proteintech™. GAPDH (#ab37168), SUMO1 (Y299, #ab32058) antibodies were from Abcam. Mouse antibodies against Flag (M2, #F1804), HA (16B12, #MMS-101P) were from Sigma. Rabbit antibodies against HA (Y-11, #sc805), Ubc9 (H-81, #sc-10,759) and mouse antibody against Lamin B1 (8D1, #sc-56,144) were from Santa Cruz Biotech. Rabbit antibody against SUMO1 (C9H1, #4940S) was from Cell Signal Technology. Alexa Fluor® 568 (Rabbit, #A11011), 488 (Rabbit, #A11008), 488 (Mouse, #A11001) were from Invitrogen.
Protein G Plus/Protein A agarose suspension (#IP05) were purchased from Calbiochem. Puromycin (#P8833), hydrogen peroxide (H2O2) solution (#H1009), insulin (#I-5500), LY294002 (#L9908) and EGF (#E9644) were from Sigma.
Plasmids
The pEGFP-6xHis-FLKHSRP plasmid was from Addgene [
11]. The FLKHSRP (full-length KHSRP) was amplified by PCR, and subcloned into the pEF-5HA vector with
EcoRI and
XbaI sites, the pCMV-Tag2B vector with
EcoRI and
XhoI sites, the pGEX-4T-1 vector with
EcoRI and
XhoI sites, respectively. Point mutations (K87R, K359R, K628R, S193A, S193D, K244R, K251R, K435R, K473R and K494R) and nuclear localization sequence (NLS) deletion mutant of KHSRP (KHSRPΔNLS) were carried out by using KOD-plus-mutagenesis Kit (TOYOBO) according to the manual. The pEF-5HA-KHSRPΔN (N-terminal aa 1–67 was deleted) was amplified from Flag-KHSRPΔN which was kindly provided by Michael G. Rosenfeld’s Lab [
7] by using KOD plus (TOYOBO) and subcloned into the pEF-5HA vector with
EcoRI and
XbaI sites. The KHSRP cDNA was amplified from pCMV-Tag2B-KHSRP with the primer containing KOZAK (GCCACC) and HA tag sequence, and then subcloned into the lentiviral vector CD513B (System Biosciences) carrying EGFP and puromycin genes. The shRNA anti-KHSRP were obtained from Sigma and sub-cloned into pLKO.1 vector.
Flag-SUMO1-KHSRPΔN plasmid was constructed by two steps. Firstly, KHSRPΔN was amplified from pEF-5HA-KHSRPΔN by using KOD plus (TOYOBO) with 10% DMSO, and then subcloned into the pCMV-Tag2B vector with
SalI and
XhoI sites. Secondly, SUMO1 (amino acids 2–96) was amplified from His-SUMO1 and inserted into of pCMV-Tag2B-KHSRPΔN with
HindIII and
SalI sites. All above plasmids were verified by sequencing. Primers used for constructions are shown in Additional file
16: Table S5.
SUMOylation assays
(A) SUMOylation of KHSRP was analyzed in 293T cells by using the method of Ni
2+-NTA beads with His-tagged SUMO1, as described previously [
29,
50,
51]. (B) In vitro SUMOylation assay in
E.coli system with pE1E2SUMO1 was performed as previously described [
20,
29]. Briefly, pGEX-4T-1-KHSRP-WT was co-expressed with or without pE1E2SUMO1 plasmid in
E.coli BL21 (DE3) respectively, and then lysed by using B-PER Protein Extraction Reagent (#78248, Thermo Fisher, USA) and incubated with Glutathione sepharose 4B (GE healthcare) at 4 °C overnight. The beads bound proteins were washed for three times with lysis buffer, and subjected to Western-bot for analysis of SUMO1-modified GST-KHSRP. (C). The method of immunoprecipitation (IP) was also used to detect the SUMO1 modification of endogenous KHSRP. Briefly, 293T cells were lysed in NEM-RIPA buffer (50 mM Tris–HCl pH 7.4, 150 mM NaCl, 1% NP-40, 20 mM N-ethylmaleimide and one complete protease inhibitor cocktail). Cell lysates (1 mg) were used for immunoprecipitation. To detect the endogenous SUMO1-KHSRP in 293T cells, 5 μl of KHSRP antibody or normal IgG (as a control) was used for immunoprecipitation. Tissues were lysed in NEM-RIPA with 0.1% SDS and 5 mM EDTA, which was according to our previous study [
28] and SUMO1 antibody was used for immunoprecipitation.
Nuclear/cytosol fractionation assay
Nuclear and cytosolic fractions were extracted by Nuclear/Cytosol fractionation kit according to the manual (Nuclear/Cytosol Fractionation Kit, Catalog #K266, BioVision, BioVision Incorporated, Milpitas, CA 95035 USA). 3 × 106 of HeLa cells were harvested. One-tenth of these cells were harvested by SDS lysis as the Input for the protein expression by Western-blot, and nine-tenth of cells were extracted by Nuclear/Cytosol fractionation kit. One-fifth of both nuclear and cytoplasmic fraction was used for Western-blotting with indicated antibody.
Immunofluorescent staining
Immunofluorescent staining was performed as described previously [
28,
50]. Briefly, HeLa cells were seeded into the Poly-Lysine coated slides overnight, and then transfected with plasmids expressing Flag-KHSRPΔN, Flag-SUMO1-KHSRPΔN or Flag-KHSRPΔNLS, respectively. After 48 h, cells were fixed with 4% paraformaldehyde for 30 min and then permeabilized with 0.2% Triton X-100 for 1 h, and then incubated in the primary antibody anti-Flag (M2) (dilution 1:800) at 4 °C overnight. Cells were washed three times with PBS and then incubated in the secondary antibody (Alexa 488 anti mouse, dilution 1:500) in blocking solution for 2 h. The cells were then washed five times with PBS. DAPI (4′,6-diamidino-2-phenylindole) was added to visualize the nucleus. Images were taken with Nikon microscope.
In another experiment, HeLa cells were transfected with HA-KHSRP-WT or HA-KHSRP-K87R with GFP-SUMO1. Cells were incubated with the primary antibody anti-HA (Rabbit, dilution 1:250), with the secondary antibody Alexa 568 anti rabbit (dilution 1:500). DAPI staining was to visualize the nucleus. The images of DAPI and anti-HA were merged. The green signals indicating the expression of GFP-SUMO1 were directly observed and taken by Nikon microscope.
To detect the endogenous KHSRP in HeLa cells, KHSRP antibody (Rabbit, dilution 1:500) was used as primary antibody and Alexa 488 anti-rabbit antibody (dilution 1:500) was used as secondary antibody.
Co-immunoprecipitation (co-IP)
293T cells transfected with HA-Drosha and Flag-KHSRP-WT or -K87R, or cells transfected with Flag-DGCR8 and HA-KHSRP-WT or -K87R respectively were lysed in RIPA buffer (50 mM Tris-HCl pH = 7.4, 150 mM NaCl, 1% NP40, 10% glycerol and a complete protease inhibitor cocktail (Roche)). 1 mg of total extracted proteins were incubated with 25 μl of protein A/G agarose and 2 μg of anti-Flag antibody at 4 °C overnight. Then the beads were washed with RIPA buffer for three times, and followed by Western blot analysis.
High-throughput miRNA sequencing
The method of high-throughput sequencing was previously described [
52]. Briefly, total RNAs from DU145 stable cell lines were extracted by Trizol (Life Technologies, Carlsbad, CA). The RNAseq library of miRNA was prepared using NEBNext® Multiplex Small RNA Library Prep Set for Illumina (NEB, Beverly, MA). Modified RNAs were reversely transcribed and then PCR amplified with specific primers corresponding to the adapters. The amplified products were resolved in 6% PAGE and the bands corresponding to ~140 bp were isolated. The libraries were quality controlled with a Bioanalyzer 2100 (Agilent, Santa Clara, CA) and sequenced by Nextseq 500 (Illumina, San Diego, CA) on a 75 bp single-end run.
RNAseq analysis
The raw sequencing reads from the small RNA libraries were mapped to the human genome (hg19) using the mapper.pl script included in miRDeep2 program with the following parameters: -l,-k,-e,-h,-j,-m. This clipped the adapter sequence from each read while keeping only reads no shorter than 18 nt. Specifically, the mapper.pl package takes Bowtie2 as the mapping engine and generated a collapsed set of non-redundant reads along with the mapped genomic locations. Then the quantifier.pl script was used to calculate the expression level of known microRNAs from the annotation of miRBase (Release 21). Additionally, the normalized abundance (RPM, Reads Per Million) for each known microRNAs was calculated as following:
$$ {RPM}_i=1000,000\times \frac{R_i}{N_j} $$
Where Ri represents the count of reads mapped to the genomic region of a given microRNA i. And Nj represents the total count of reads in the small RNA library of sample j.
RNA immunoprecipitation assay (RIP)
The RNA immunoprecipitation assay (RIP) was performed as previously described [
20,
26]. Briefly, 48 h after transfection with the indicated plasmids, one-tenth of these cells in 10-cm plate cultured were reserved as the Input for qRT-PCR analysis, and nine-tenth of cells were lysed in RIP buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.4, 1% NP40, 1 mM DTT, 100 units/ml RNase inhibitor (Fermentas), 400 μM VRC (New England BioLabs), Protease inhibitor cocktail (Roche)). After incubated on ice for 1 h, 1/50 of lysates were used for Western blot to examine the expression of KHSRP, the others were incubated with 40 μl of protein A/G agarose and 4 μg of anti-Flag antibody at 4 °C overnight. After immunoprecipitation, the beads were washed with RIP-lysis buffer for three times and then 1/10 of the beads were immunoblotted for the efficiency analysis of immunoprecipitation. The remaining beads were used to extract RNA by Trizol reagent (Invitrogen).
qRT-PCR analysis
Quantitative real-time PCR was performed with SYBR® Green PCR Master Mix (#4309155, Applied Biosystems, USA) to analyze the fold changes of pri-miRNAs immunoprecipitated by KHSRP and mature miRNAs biogenesis. GAPDH and U6 levels were used for normalization of pri-miRNAs and mature miRNAs PCR and the pri-miRNAs immunoprecipitated by KHSRP was normalized by Input of pri-miRNAs.
The soft-agar colony forming assay was performed as described previously [
20,
26,
50]. Briefly, this assay was performed in 6-well plates with a base of 2 ml of medium containing 5% FBS with 0.6% Bacto agar (Amresco). Cells were seeded in 2 ml of medium containing 5% FBS with 0.35% agar at 2 × 10
3 (for DU145 cells) cells/well and layered onto the base. 2 ml of DMEM with 10% FBS was covered on the top of agar gel. The photographs of colonies growing in the plates were taken at day 21. The number of colonies was scored by photoshop CS5.
Migration assay by RTCA-DP
The procedure was carried out as previously described [
20,
26]. Briefly, 4 × 10
4 of each of serum-starved DU145 stable cells were suspended in 100 μl of serum-free medium, and then cell suspension was added into the pre-equilibrated upper chamber of CIM-plate. The lower chamber was filled with 160 μl of complete DMEM containing 10% FBS. The kinetic cell index of migration was recorded every 15 min for 24 h and then calculated by RTCA software v1.2 (Roche Applied Science).
Vasculogenic mimicry (VM) assay
The vasculogenic mimicry experiment of DU145 stable cells were carried out using μ-Slide Angiogenesis Kit (IBIDI) according to the procedure as previously described [
39,
53]. DU145 cells at the density of 5 × 10
3 in 50 μl of growth medium were plated in each well pre-coated with matrix™ (Millipore). Pictures were taken with Nikon microscope 20 h later.
Three-dimensional (3D) cell culture assay
The 3D cell culture assay was performed as described before [
39]. Generally, 5 μl of 3D matrix™ (Millipore) and 5 μl of cell solution (2 × 10
3 cells) were mixed and added into the inner well of μ-Slides (IBIDI) and covered with complete cell culture medium. The μ-slides were incubated at 37 °C and 5% CO
2 cell incubator for 7 days and pictures were taken with Nikon microscope.
Xenograft tumor model
The experiment of xenograft tumor model was conducted as previously described [
20,
50]. Stable DU145 cell lines (2.5 × 10
6) were injected subcutaneously into 5-week-old male BALB/c nude mice (
n = 5) individually. 15 days after injection, the tumors were measured every 6 days. All mice were sacrificed at 35 days and the tumors were dissected, photographed and weighed. All animal studies were conducted with the approval and guidance of Shanghai Jiao Tong University Medical Animal Ethics Committees.
Statistical analysis
Experiments were performed at least three times, and representative results were shown. All data are presented as means ± s.e.m. for qPCR, RTCA migration, mouse xenograft model and soft agar colony forming assay. Statistical analysis was calculated with Microsoft Excel analysis tools. Differences between individual groups are analyzed using the t-test (two-tailed and unpaired) with triplicate or quadruplicate sets. A value of P < 0.05 was considered statistically significant and P-value <0.05 was marked with (*), < 0.01 with (**) or <0.001 with (***). TCGA data was analyzed by Pearson Correlation method by the program SPSS 22.